Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Quidel Corporation
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.
An alert from the agency warns that the tests, which have become widely used for their speed and portability, carry a risk of false positives.
Germany is adjusting the national COVID-19 testing strategy, which from mid-October will include the use of antigen tests.
The US FDA’s diagnostics chief says the agency isn’t seeing many submissions for rapid antigen tests, but is eager to authorize them.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Therapeutic Drug Monitoring
- Other Names / Subsidiaries
- BioHelix Corporation
- Diagnostic Hybrids, Inc.